Testicular toxicity is an important safety endpoint in drug development and risk assessment, but reliable and translatable biomarkers for predicting injury have eluded researchers. However, this area shows great potential for improvement, with several avenues currently being pursued. This was the topic of a symposium session during the 2013 Society of Toxicology Annual Meeting in San Antonio, TX, entitled "Translatable Indicators of Testicular Toxicity: Inhibin B, MicroRNAs, and Sperm Signatures." This symposium brought together stakeholders from academia, government, and industry to present the limitations and drawbacks of currently used indicators of injury and discussed the ongoing efforts in developing more predictive biomarkers of injury. The presentations highlighted the early challenges of using circulating inhibin B and microRNA levels, and sperm messenger RNA transcript abundance and DNA methylation profiles, as novel biomarkers of testicular toxicity.
The pharmaceutical drug development process takes years and is estimated to cost in excess of US$1 billion to bring a single product to market. The development of predictive biomarkers will potentially streamline the process and is expected to significantly reduce the development costs (Crawford, 2004) . The testis is one of many tissues routinely assessed histologically in nonclinical studies; histopathological findings in animal studies that affect the safety profile of any drug candidate slow down and complicate the cross-species extrapolation to humans during the development process (Sasaki et al., 2011) . There are currently no translatable biomarkers for seminiferous tubule damage; therefore, testicular damage observed in preclinical studies at a low margin of exposure is often evaluated separately in human semen studies. Further clinical studies examining functional endpoints (eg, semen parameters) may be necessary to determine if adverse findings in an animal model translates to an adverse response in humans. Thus, a sensitive translatable biomarker would allow the pharmaceutical industry to rapidly identify testicular toxicity in preclinical and in clinical studies, while significantly decreasing the time and resources needed to evaluate some drug candidates, and also increasing the safety of clinical trial volunteers and patients. Efforts are ongoing to develop translational safety biomarkers that can serve to enhance pharmaceutical development and act as indicators of harmful environmental exposures (Sistare and DeGeorge, 2011) .
Toxicants and pharmaceutical compounds can adversely affect the male reproductive tract by targeting different cell types of the testis (ie, germ, Leydig, and Sertoli cells) and altering hormone levels via the hypothalamic-pituitary-gonadal axis. Semen parameters may also be affected, resulting in a decline in sperm health and/or function. Decreases in testis weight can be a sensitive indicator of moderate damage in preclinical studies, but this is not feasible clinically. Similarly, testicular histopathology, the gold standard for measuring testicular injury, is not possible in a clinical setting and raises the need for a noninvasive measure. In addition to being minimally invasive, an ideal testicular toxicity biomarker will serve a wide range of purposes in drug development, clinical trials, and risk assessment strategies. In order to achieve this, a biomarker must possess at least the following characteristics:
(1) Easily accessible and measurable in bodily fluids (blood, semen, or urine).
(2) Stable in the biological medium.
(3) Sensitive and proportional to changes in testicular histopathology.
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(4) Report injury before irreversible damage occurs.
(5) Provide a robust and detectable response that is rapid and simple to assess in all test species.
Surrogates of testicular toxicity have actively been investigated and are summarized in Table 1 . The most commonly used translatable indicators from preclinical to clinical testing are sperm parameters and circulating hormone levels (testosterone, luteinizing hormone, and follicle-stimulating hormone [FSH] ). Epididymal sperm samples are easily obtainable during animal necropsy, whereas human semen can be collected in a clinical setting. However, semen parameters are highly variable both within and between individuals (eg, Schrader et al., 1991; Wijchman et al., 2001) . Circulating serum hormone measurements are also easily measured but are generally unreliable at detecting mild injury to the seminiferous epithelium (Buck et al., 2008; Camacho et al., 2012; Creasy, 1999; Knobil and Neill, 2005) ( Fig. 1) , so that only severe, and potentially irreversible germinal epithelial injuries are likely to be detected. Most importantly, perturbations in either semen parameters or hormone levels are often simply not associated with changes in testicular histopathology (Buck et al., 2008; Creasy, 1999) . All of these highlight the need for more sensitive, specific, and robust biomarkers of toxicity. At the Society of Toxicology's 52nd Annual Meeting, a symposium session was held that reviewed the current state of testicular biomarkers and recent advancements in the field, which focused on the use of circulating inhibin B and microRNAs (miRNAs), and sperm DNA methylation marks and messenger RNA (mRNA) transcripts as indicators of testicular damage and toxicity.
Inhibin B
Inhibin B is a heterodimeric glycoprotein that negatively regulates FSH and is predominantly produced by Sertoli cells (Burger and Igarashi, 1988; Stewart and Turner, 2005) . Circulating inhibin B levels in human males vary throughout life; levels rise from birth through the first few months of age to levels comparable or exceeding those of adults, decrease through mid-childhood, and then increase again at the start of puberty (Andersson et al., 1997 (Andersson et al., , 1998 Byrd et al., 1998;  Blanco and Zinkham (1963) , Burgos et al. (1979) , Timbrell (1998), Gerez deBurgos et al. (1979) , Lalwani et al. (1996) , Odet et al. (2008) , Orlando et al. (1988) , Reader et al. (1991) , and Zinkham et al. (1964) 
Creatine
• Released in the urine after testicular damage
• Associated with, but does not precede damage Butterworth et al. (1995) , Draper and Timbrell (1998) , Draper et al. (1994) , Gray et al. (1990) , Moore et al. (1992) , and Timbrell et al. (1995) • Crofton et al., 1997) . Basal adult levels of inhibin B are established during puberty, which corresponds with the end of Sertoli cell proliferation and start of spermatogenesis, and large changes in inhibin B levels are generally reflective of germ cell proliferation in the testes (Petersen et al., 1999) . Epidemiologic evidence and data from infertility clinics support the hypothesis that circulating inhibin B levels are useful indicators of testicular function. Serum inhibin B levels are roughly correlated with sperm concentration among men undergoing evaluation for male factor infertility and are used clinically to place patients into fertility categories (McNeilly, 2012) . In humans, a change in inhibin B levels requires significant structural damage in the testis and is typically used to assess chronic lesions.
Recently, the Health and Environment Sciences Institute's Developmental Reproductive Toxicity Technical Committee (HESI DART) hosted a consortium of companies to evaluate inhibin B as a potential biomarker for testicular toxicity and summarized the results . The HESI DART project had 2 overall objectives:
(1) Evaluate the analytic performance of a new ELISA kit for measuring rat inhibin B. (2) Determine the relationship between changes in circulating inhibin B and the development of testicular pathology in rats following toxicant exposures.
The HESI DART consortium had earlier sought to validate a previous version of the clinical ELISA kit from Diagnostic Systems Laboratories for measuring circulating inhibin B levels in rats. Evaluation of the kit uncovered performance issues related to the antibody that postponed the project until the release of the second-generation ELISA kit from Beckman Coulter that utilizes a new antibody. Although this kit is marketed for analyzing human samples, the antibody cross-reacts with rat and monkey, and 5 laboratories (AstraZeneca, Pfizer, Janssen, Merck, and Sanofi) evaluated its technical performance with rat serum/plasma. Generally, the kit performed well with rat samples but had increased variability at the lower end of the detection range (Coulson et al., 2013a) .
fIg. 1.
Testicular lesions produced in an adult rat after 8 days of dosing with an antibiotic pharmaceutical candidate. Note the multinucleated giant cells (arrows) containing spermatocytes, absence of germ cell cohorts, and disorganization of the seminiferous epithelium. Accessory sex organ weights and histology were unchanged by this compound at any dose or time, consistent with a lack of hormonal changes. Scale bar = 50µM. Original magnification: ×200.
Beyond technical performance, the consortium was most interested in the correlation between decreases in circulating inhibin B levels and the development of testicular pathology in the rat; therefore, a series of rat pathogenesis studies were conducted with approximately 20 different compounds (Table 2) covering diverse mechanisms of testicular toxicity across different laboratories (AbbVie, AstraZeneca, Boehringer Ingelheim, Covance, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Pfizer, and Sanofi) and reported in a special issue of Birth Defects Research Part B (98[1], 2013) (Breslin et al., 2013; Chapin and Kim, 2013; Chapin et al., 2013a Chapin et al., , 2013b Coulson et al., 2013b; Enright et al., 2013; Erdos et al., 2013; Moffit et al., 2013; Pfaff et al., 2013; Sonee et al., 2013; Stewart et al., 2013; Ziejewski et al., 2013) . Exposure scenarios and recovery periods varied between companies to reflect real-world testing strategies. In all cases, inhibin B levels and testicular histopathology were assessed. The temporal profile of inhibin B was elevated in younger animals and exhibited an age-dependent decline to reach stable concentrations in adult animals, consistent with previous reports (Buzzard et al., 2004; Sharpe et al., 1999) . Interestingly, the HESI DART project found differences in circulating inhibin B levels between Wistar Han and Sprague Dawley rat strains. Control animal data also demonstrated considerable variation especially at lower concentrations (< 30 pg/ ml), which are in part due to both the assay precision at the lower end of the detection range and the interanimal variation of inhibin B levels. This issue raises concerns regarding the ability to accurately detect treatment-related decreases in inhibin B levels, particularly in laboratories where inhibin B concentrations are low in control animals.
The large scale of this multi-corporation consortium study was able to confirm inhibin B decreases after sufficient damage, regardless of mechanism or toxicant class (Chapin et al., 2013b; Coulson et al., 2013b; Enright et al., 2013; Erdos et al., 2013; Sonee et al., 2013) . However, analytic and interanimal variability will make it difficult to sensitively and reliably detect treatment-related decreases (Breslin et al., 2013; Chapin et al., 2013b; Ziejewski et al., 2013) . Decreases in inhibin B were detected when significant testicular lesions were observed; however, decreases were generally not detected with less severe pathology or prior to the development of notable pathology.
At the other end of the spectrum, the kit also reported decreases in circulating inhibin B in the absence of detectable pathology. There were some exposures for which inhibin B was found to be a useful biomarker (Coulson et al., 2013b; Erdos et al., 2013) , but overall, the relationship between circulating inhibin B and testis damage was uneven and unreliable. Despite the technical improvements of the second-generation diagnostic kit and its potential clinical applications in men, changes in inhibin B levels lack sufficient consistency, sensitivity, and specificity in the rat, all required characteristics of a practical and informative biomarker.
MicroRNAs
MicroRNAs are approximately 22-nucleotide, singlestranded, noncoding RNAs that are involved in regulating gene expression through sequence-specific base pairing with target gene transcripts (Bartel, 2004) and have critical regulatory roles in a variety of disease states (Geekiyanage and Chan, 2011; Hudson et al., 2011; Kalis et al., 2011; Siegel et al., 2012) . In animals, miRNAs are phylogenetically conserved and primarily inhibit transcript translation by binding in the 3′ untranslated region (UTR) sequences of targeted gene transcripts (Bartel, 2004; Lee et al., 1993; Wightman et al., 1993) . However, there is growing evidence that miRNAs also posttranscriptionally regulate gene expression through complementary binding in the 5′ UTRs (Lee et al., 2009; Lytle et al., 2007; Moretti et al., 2010) and coding regions (Tay et al., 2008; Zhou et al., 2009) . Recent studies have also demonstrated that miRNAs can bind at promoter sequences to regulate target gene expression at the transcriptional level (Kim et al., 2008; Place et al., 2008) . miRNAs are expressed endogenously within cells and it has been hypothesized that every animal cell type at each developmental stage may carry a specific miRNA profile to regulate its transcriptome (Bartel, 2004) . Secreted miRNAs can circulate in microparticles and be delivered to target cells to regulate gene expression (Zernecke et al., 2009; Zhang et al., 2010) .
It has been previously shown that miRNAs have critical roles during spermatogenesis. Loss of miRNAs in the testes due to conditional knockdowns of the miRNA machinery in both germ cells and Sertoli cells has resulted in aberrant spermatogenesis. Germ cells lacking Dicer, a protein involved in the maturation of miRNA from precursor miRNA, have reduced miRNA levels that result in late-onset adult subfertility and infertility due to defects in both spermatogonial proliferation/differentiation and aberrant transitions from round to elongating spermatids (Hayashi et al., 2008; Maatouk et al., 2008) . Additionally, loss of Dicer in Sertoli cells results in a complete depletion of spermatozoa and ultimately culminates in testicular degeneration (Papaioannou et al., 2009) . These studies clearly indicate the critical importance of miRNAs in the normal development of spermatozoa.
Similar to the approach taken with exploring inhibin B as a potential biomarker, an industry consortium under the aegis of the Predictive Safety Testing Consortium (PSTC) at the Critical (Goodsaid et al., 2007) is investigating the use of circulating miRNAs as indicators of testicular damage. The consortium effort is in its early stages but has built upon the existing body of work from Pfizer by profiling a multitude of tissues and blood for miRNAs, specifically those that were previously reported to be found in the testis. The list of miRNAs was further refined based on the robustness of the screening results and for associations with pathogenesis studies. Pfizer investigated these miRNAs in response to testis-specific (ethylene glycol monomethylether [EGME] and 1,3-dinitrobenzene [1,3-DNB]) and nonspecific (ethylene glycol mono-n-butyl ether and 1,4-dinitrobenzene [1,4-DNB]) toxicants. Testicular lesions of varying severity were observed only in EGME and 1,3-DNB-treated rats after 5 and 8 days of treatment (the only 2 times examined in those studies). Blood drawn after 2 days contained elevated levels of 2 miRNAs, miR-202 and miR-741, associated with only EGME or 1,3-DNB treatments, thereby providing evidence that miRNAs can potentially be used as suitable indicators of injury. However, only these 2 miRNAs were altered of the 22 miRNAs profiled. Additionally, not all rats with testicular lesions possessed elevated levels of these miRNAs, demonstrating that there is no clear association between testicular lesion severities with miRNA increase. Pfizer's experience to date indicates problems with both sensitivity and specificity.
Investigators from Eli Lilly have also examined circulating miRNA levels following treatments with carbendazim (CBZ), 1,3-DNB, or mono(2-ethylhexyl) phthalate. Their results identified elevated levels of only miR-202 and miR-202* following treatment with these testicular toxicants. The response of miR-202 was the most robust and was detected at all doses of 1,3-DNB and CBZ. However, as with the findings from Pfizer, not all treated animals had elevated levels of miR-202. Future dose-response studies by Eli Lilly will evaluate the sensitivity of miRNA detection in relation to testicular histopathology.
The findings from both Pfizer and Eli Lilly have demonstrated promising results showing that circulating miRNAs can potentially be used as indicators of seminiferous tubule damage. However, the initial results from both companies raise concerns regarding the assay sensitivity. Efforts to troubleshoot these methods and optimize the detection of miRNA levels are currently in progress. Following further refinements, the assays will ideally detect additional testicular toxicant-sensitive miRNAs and identify an association between miRNA levels and degree of testicular damage.
SpeRM MoleculAR MARkeRS
The sperm transcriptome contains approximately 40% of the testicular mRNA population and can be used to monitor gene expression during spermatogenesis (Ostermeier et al., 2002) . Studies have demonstrated an association between sperm mRNA levels and men with infertility issues (Aoki et al., 2006; Steger et al., 2008; Wang et al., 2004) . These sperm mRNAs may be passively retained or play an active role in chromatin structure, imprinting, gene silencing, and embryogenesis (Miller and Ostermeier, 2006) . Additionally, methylation of sperm DNA can also provide insight into disrupted spermatogenesis. It has been clearly established that the germline DNA is actively demethylated and remethylated during spermatogenesis (Trasler, 2006) and aberrant methylation profiles may be implicated in testicular dysfunction. Recent studies have demonstrated that rats treated with chemotherapeutics (Chan et al., 2012) and tamoxifen (Pathak et al., 2009 ) develop altered sperm DNA methylation profiles. In summary, sperm mRNA transcripts and DNA methylation marks are acquired during spermatogenesis and reflect the integrity of that process. Assessment of these sperm molecular marks can provide valuable insight into the testicular response to pharmaceutical and environmental occupational chemical exposures.
A panel of sperm mRNA transcripts that can detect and predict low-level exposures to Sertoli cell toxicants in rats (as exemplified by the prototypic toxicant 2,5-hexanedione [2,5-HD]) has been developed (Pacheco et al., 2012) . The 12-transcript PCR array panel was developed by treating rats with 2,5-HD for 3 months at levels that produced minimal testicular injury, followed by a 3-month recovery period. This exposure paradigm was used repeatedly to select altered transcripts from whole-genome microarrays for the PCR arrays and to refine the PCR array panel. Genome-wide profiling identified 128 significantly altered transcripts from which an initial 29-transcript PCR array panel was developed and then further refined to generate a 12-transcript panel. Transcripts were chosen for the PCR arrays based on exposure-related fold change and known expression and function within the testis. With each refinement of the PCR array panel, the yield of significantly altered transcripts among those measured improved.
The sensitivity of the selected 12-transcript PCR array panel was tested in rats following exposure to 2,5-HD and CBZ across a dose-response range including the lowest observed adverse effect level. Although both 2,5-HD and CBZ are Sertoli cell toxicants, only 4 altered transcripts (Abi2, Clu, Ptgds, and Sod3) were common between them, and they were altered in a compound-specific manner (Pacheco et al., 2011) . This may reflect the differences in their toxicity mechanisms of action; 2,5-HD promotes and stabilizes, whereas CBZ inhibits, microtubule assembly (Howard and Aist, 1980; Moffit et al., 2007; Quinlan et al., 1980; Winder et al., 2001) . Despite their opposing effects on microtubule assembly, exposure to low levels of either compound resulted in a significant increase of retained spermatid heads (RSH) in the seminiferous epithelium associated with changes in sperm mRNA transcript abundance. One transcript in particular, clusterin (Clu), was sensitive enough to detect exposures to CBZ before any changes in RSH were observed. Further testing and refining of the 12-transcript PCR array panel has been performed using 17 exposure groups to date; this includes exposure to a germ cell toxicant 269 (1,2-dibromo-3-chloropropane [DBCP]), as well as multiple time points of both exposure, and recovery from exposure. Inclusion of germ cell toxicants will expand the PCR array panel to capture responses to a range of testicular toxicant types.
In addition to creating the PCR array panel from the rat studies, ongoing research has investigated the relationship between semen parameters with the sperm mRNA transcripts and CpG methylation profiles in men (Pacheco et al., 2011) . Methylation analysis of low motility sperm found that 34% of the CpGs analyzed were aberrantly methylated. Furthermore, 80% of these altered CpGs were hypomethylated. Sperm mRNA profiling identified changes in 20 genes that included imprinted genes, and genes associated with spermatogenesis and epigenetic regulation. Most notably, these included increases in HDAC1 and DNMT3A levels, and a decrease in SIRT3, all of which are key in controlling epigenetic marks on DNA and histones. Integration of the human methylation and transcriptomic data identified an association between globally hypomethylated low motility sperm with perturbed mRNA transcript levels. DNA hypomethylation and changes in mRNA levels may result in abnormal chromatin compaction or increased intracellular oxidative stress and negatively impact normal epigenetic regulation.
Collectively, this body of work using model testicular toxicants has demonstrated that sperm molecular biomarkers are potentially sensitive and predictive indicators of damage. In addition to refining the PCR array panel with DBCP, a germ cell toxicant, other cell type-specific toxicants, and mixtures of toxicants will be explored in future rat studies. Clinically, there are a vast number of exposure scenarios that can be pursued, such as examining the molecular profiles of men using pharmaceutical drugs like statins, or smokers, obese individuals, or patients undergoing chemotherapy treatment. Because spermatogenesis requires weeks to produce mature sperm, sperm molecular profiling is best suited for reporting chronic or subchronic exposure scenarios, and not acute effects.
Although not addressed in the symposium, the sperm proteome is another potential target of reproductive toxicants, which can be profiled for biomarkers of injury. Sensitive proteomic techniques have already identified posttranslational protein modifications in human sperm following in vitro nitric oxide exposure (Lefièvre et al., 2007) . Both transcriptomic and proteomic approaches are well suited for prolonged longitudinal and chronic exposure studies and are valuable endpoints that should be incorporated into future epidemiological studies.
coNcluSIoNS
Although testicular histopathology is often considered the gold standard of testicular damage nonclinically, semen parameters and circulating hormone levels are commonly used noninvasive indicators of testicular damage. However, these latter endpoints are highly variable and inconsistent with reference to testicular injury. In most cases, changes are only observed when severe and potentially irreversible damage has occurred. Therefore, there is still considerable interest and ongoing efforts devoted to developing translatable, sensitive, and predictive biomarkers of testicular toxicity. These consortia and academic efforts will expand and include a suite of chemicals that target susceptible cells including Leydig, Sertoli, and germ cells. The disappointments in inhibin B are counterbalanced by the promise of circulating miRNAs and by the capabilities of longer term monitoring strategies that are inherent in the use of sperm mRNAs. Despite the challenges and setbacks, we remain optimistic that these efforts will pay off by revealing a biomarker useful both in the clinic and in public health surveillance. 
